Tesamorelin for Fat Loss: Dosing, Results, and What to Expect (2026)

Tesamorelin: What It Is and Why It Works for Fat Loss

Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue — a peptide that stimulates the pituitary gland to produce more natural growth hormone (GH). Unlike synthetic HGH injections, tesamorelin works by triggering your own pituitary to pulse GH in a more physiological pattern. The result: targeted reduction of visceral adipose tissue (VAT) — the deep abdominal fat that accumulates with age, low testosterone, and metabolic dysfunction.

It’s FDA-approved under the brand name Egrifta for HIV-associated lipodystrophy, which established a strong clinical evidence base for visceral fat reduction that physicians now apply to age-related abdominal fat accumulation in metabolically dysregulated patients.

How Tesamorelin Reduces Visceral Fat

The mechanism is direct and well-understood:

1. Tesamorelin binds to GHRH receptors on pituitary somatotrophs
2. Pituitary releases growth hormone in pulsatile bursts (mimics natural GH rhythm)
3. GH triggers IGF-1 production in the liver
4. Elevated GH + IGF-1 activates lipolysis (fat breakdown) preferentially in visceral adipose tissue
5. VAT reduction occurs — measurable by CT scan and waist circumference

What makes tesamorelin different from general weight loss approaches is target specificity. It doesn’t just shrink subcutaneous fat (the fat under your skin) — it specifically attacks visceral fat, which is metabolically active, inflammatory, and resistant to diet and exercise in older men.

Clinical Results: What Studies Show

Real-world results in non-HIV patients with age-related abdominal fat accumulation tend to mirror these findings — 15-25% reduction in visceral fat over 3-6 months of consistent use, with the most dramatic results in men who also address testosterone deficiency and lifestyle factors.

Dosing Protocol

The standard clinical dose of tesamorelin for visceral fat reduction:

• Dose: 1 mg subcutaneous injection, once daily
• Timing: Before bed (aligns with natural GH secretion peak during sleep) or morning fasted
• Cycle: Continuous use for 3-6 months for meaningful reduction; can be sustained longer under physician supervision
• Site rotation: Abdomen, thighs, or upper arms — rotate to avoid lipohypertrophy

Some protocols use 2 mg/day for faster results, though the incremental benefit above 1 mg is modest and increases cost and side effect potential. Viking typically starts at 1 mg/day and adjusts based on IGF-1 response and tolerance.

What to Expect: Timeline

• Weeks 1-4: Minimal visible change; IGF-1 rising; some patients report better sleep quality and energy
• Weeks 4-8: Some patients notice early reduction in abdominal fullness; water retention in some cases (transient)
• Months 2-4: Most patients see measurable waist reduction; visceral fat trending down on any imaging done
• Months 4-6: Peak clinical response window; 15-20% VAT reduction typical in responsive patients
• After stopping: VAT creeps back over 12-24 weeks without ongoing treatment; lifestyle changes help preserve gains

Side Effects and Monitoring

Tesamorelin is generally well-tolerated. Known side effects:

• Common: Injection site reactions (redness, itching) — usually transient
• Less common: Peripheral edema (water retention in hands/feet), joint pain, myalgia — often dose-dependent
• Monitor: IGF-1 levels (should stay within physiological range, not supraphysiologic); glucose (GH slightly elevates blood sugar — important for pre-diabetics)
• Contraindications: Active malignancy, pregnancy, known GHRH hypersensitivity

Viking monitors IGF-1 at baseline and during treatment to confirm response and ensure levels remain physiological rather than supraphysiologic.

Tesamorelin vs Other Fat Loss Peptides

Tesamorelin at Viking Alternative Medicine

Viking includes tesamorelin in its peptide optimization toolkit for men with significant visceral fat accumulation, particularly those also on TRT. The synergy is real: testosterone addresses the hormonal environment (improves insulin sensitivity, muscle mass, motivation), while tesamorelin specifically targets the visceral fat depot that TRT alone doesn’t fully address in men with established metabolic dysfunction.

The combination of TRT + tesamorelin is one of the more powerful body composition protocols available in clinical telehealth — and Viking is one of a small number of clinics offering both under physician supervision with appropriate monitoring.

Frequently Asked Questions

How much visceral fat does tesamorelin actually reduce?

Clinical studies show 15-20% reduction in visceral adipose tissue over 6 months of daily use at 1 mg. Real-world results vary by baseline VAT, diet, activity level, and hormonal optimization (men on concurrent TRT tend to respond better).

Does tesamorelin work without diet and exercise?

Yes — studies show statistically significant VAT reduction even without lifestyle changes. But combining tesamorelin with a caloric deficit and resistance training produces meaningfully better results. Think of it as accelerating an optimized metabolic environment, not replacing one.

How long do you need to take tesamorelin?

VAT reduction is sustained during treatment but reverses over 12-24 weeks after stopping. Most patients use it for 3-6 month cycles, then reassess. Some continue long-term under physician monitoring, particularly when paired with TRT for ongoing metabolic optimization.

Is tesamorelin the same as HGH?

No. Tesamorelin is a GHRH analogue — it stimulates your pituitary to produce more of your own growth hormone in a pulsatile, physiological pattern. Synthetic HGH (somatropin) is an exogenous GH injection that bypasses the pituitary entirely, providing supraphysiologic and non-pulsatile GH. Tesamorelin’s approach is more physiological and carries a better safety profile for long-term use.